Financial Projections - The company expects a net profit attributable to shareholders of between 28.61 million and 42.16 million yuan for 2025, representing a decline of 50.70% to 66.55% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be between 7.45 million and 10.97 million yuan, reflecting a decrease of 80.33% to 86.65% year-over-year[3] Performance Challenges - The decline in performance is attributed to intensified competition in the generic drug industry and fluctuations in customer demand, leading to a decrease in revenue scale and gross margin[5] Strategic Initiatives - The company is actively optimizing operational efficiency and enhancing its R&D system to strengthen resilience in a challenging market environment[6]
万邦医药(301520) - 2025 Q4 - 年度业绩预告